First-line (1-L) bevacizumab plus chemotherapy (Bev/CT) in colorectal cancer (CRC) patients with potentially resectable liver only (LM) or liver and lung metastases (LLM): KRAS mutation analysis of the non-interventional PICASSO study
2016
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI